Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort

PRIMA Initiative Group

doi:10.1186/s12879-022-07107-w

Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort

PRIMA Initiative Group

Center for Neurogenomics and Cognitive Research

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

Background: Many studies support the protective effect of breastfeeding on respiratory tract infections. Although infant formulas have been developed to provide adequate nutritional solutions, many components in human milk contributing to the protection of newborns and aiding immune development still need to be identified. In this paper we present the methodology of the “Protecting against Respiratory tract lnfections through human Milk Analysis” (PRIMA) cohort, which is an observational, prospective and multi-centre birth cohort aiming to identify novel functions of components in human milk that are protective against respiratory tract infections and allergic diseases early in life.

Methods: For the PRIMA human milk cohort we aim to recruit 1000 mother–child pairs in the first month postpartum. At one week, one, three, and six months after birth, fresh human milk samples will be collected and processed. In order to identify protective components, the level of pathogen specific antibodies, T cell composition, Human milk oligosaccharides, as well as extracellular vesicles (EVs) will be analysed, in the milk samples in relation to clinical data which are collected using two-weekly parental questionnaires. The primary outcome of this study is the number of parent-reported medically attended respiratory infections. Secondary outcomes that will be measured are physician diagnosed (respiratory) infections and allergies during the first year of life.

Discussion: The PRIMA human milk cohort will be a large prospective healthy birth cohort in which we will use an integrated, multidisciplinary approach to identify the longitudinal effect human milk components that play a role in preventing (respiratory) infections and allergies during the first year of life. Ultimately, we believe that this study will provide novel insights into immunomodulatory components in human milk. This may allow for optimizing formula feeding for all non-breastfed infants.

Original language	English
Article number	152
Pages (from-to)	1-10
Number of pages	10
Journal	BMC Infectious Diseases
Volume	22
Issue number	1
Early online date	14 Feb 2022
DOIs	https://doi.org/10.1186/s12879-022-07107-w
Publication status	Published - Dec 2022

Bibliographical note

Funding

The study was funded by grants from the Dutch Ministry of Health, Welfare and Sport, the Wilhelmina Children’s Hospital and Nutricia B.V. None of the authors have a competing financial interest in relation to the presented work; JG, LK and BL are (partly) employed by Danone Nutricia Research. This research was supported by Regio Deal Foodvalley (grant nr 162135), the WKZ research fund-Nutricia call 2020 “Breast milk T cells: frontline protection for infants and mothers?” and from Danone Nutricia Research BV as part of a UMC Utrecht-Danone Nutricia Research BV collaboration grant “Early Life Nutrition and Immune Development” (Ministerie van Volksgezondheid, Welzijn en Sport, Universitair Medisch Centrum Utrecht, Danone Nutricia Research BV). The funders had no role in the study design, in the collection, analysis and interpretation of data. The funders had no role in the final decisions on the interpretation and dissemination of the results.

Funders	Funder number
Early Life Nutrition and Immune Development
Ministerie van Volksgezondheid, Welzijn en Sport, Universitair Medisch Centrum Utrecht
Regio Deal Foodvalley	162135
UMC Utrecht-Danone Nutricia Research BV
Wilhelmina Children’s Hospital and Nutricia B.V. None
Danone Nutricia Research
Nutricia Research Foundation	20187710
Ministerie van Volksgezondheid, Welzijn en Sport
Universitair Medisch Centrum Utrecht

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12879-022-07107-w

Persistent URL (handle)

Persistent link

Cite this

@article{c2de6912264f4bb2a8af1b6eea69eee5,

title = "Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort",

abstract = "Background: Many studies support the protective effect of breastfeeding on respiratory tract infections. Although infant formulas have been developed to provide adequate nutritional solutions, many components in human milk contributing to the protection of newborns and aiding immune development still need to be identified. In this paper we present the methodology of the “Protecting against Respiratory tract lnfections through human Milk Analysis” (PRIMA) cohort, which is an observational, prospective and multi-centre birth cohort aiming to identify novel functions of components in human milk that are protective against respiratory tract infections and allergic diseases early in life. Methods: For the PRIMA human milk cohort we aim to recruit 1000 mother–child pairs in the first month postpartum. At one week, one, three, and six months after birth, fresh human milk samples will be collected and processed. In order to identify protective components, the level of pathogen specific antibodies, T cell composition, Human milk oligosaccharides, as well as extracellular vesicles (EVs) will be analysed, in the milk samples in relation to clinical data which are collected using two-weekly parental questionnaires. The primary outcome of this study is the number of parent-reported medically attended respiratory infections. Secondary outcomes that will be measured are physician diagnosed (respiratory) infections and allergies during the first year of life. Discussion: The PRIMA human milk cohort will be a large prospective healthy birth cohort in which we will use an integrated, multidisciplinary approach to identify the longitudinal effect human milk components that play a role in preventing (respiratory) infections and allergies during the first year of life. Ultimately, we believe that this study will provide novel insights into immunomodulatory components in human milk. This may allow for optimizing formula feeding for all non-breastfed infants.",

author = "\{van Stigt\}, A.H. and \{Oude Rengerink\}, K. and K.W.M. Bloemenkamp and \{de Waal\}, W. and S.M.P.J. Prevaes and T.-M. Le and \{van Wijk\}, F. and M. Nederend and A.H. Hellinga and C.S. Lammers and \{den Hartog\}, G. and \{van Herwijnen\}, M.J.C. and J. Garssen and L.M.J. Knippels and L.M. Verhagen and \{de Theije\}, C.G.M. and A. Lopez-Rincon and J.H.W. Leusen and \{van{\textquoteright}t Land\}, B. and L. Bont and A.C. Knulst and \{van der Ent\}, C.K. and \{van Baarle\}, D. and M.H.M. Wauben and N.Y. Rots and E.A.M. Sanders and M.J.N.L. Benders and L.A.M.P. Meulenbroek and B. Stahl and A.D. Kraneveld and B.J.M. Buiteman and T. Voogt and \{van der Meij\}, B. and B. Lerkvaleekul and E. Voogd and T.A. Lalmahomed and I.M. Brus and \{van Meerwijk\}, D.M.M. and S.I.E. Jepma and \{PRIMA Initiative Group\}",

note = "{\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1186/s12879-022-07107-w",

language = "English",

volume = "22",

pages = "1--10",

journal = "BMC Infectious Diseases",

issn = "1471-2334",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort

AU - van Stigt, A.H.

AU - Oude Rengerink, K.

AU - Bloemenkamp, K.W.M.

AU - de Waal, W.

AU - Prevaes, S.M.P.J.

AU - Le, T.-M.

AU - van Wijk, F.

AU - Nederend, M.

AU - Hellinga, A.H.

AU - Lammers, C.S.

AU - den Hartog, G.

AU - van Herwijnen, M.J.C.

AU - Garssen, J.

AU - Knippels, L.M.J.

AU - Verhagen, L.M.

AU - de Theije, C.G.M.

AU - Lopez-Rincon, A.

AU - Leusen, J.H.W.

AU - van’t Land, B.

AU - Bont, L.

AU - Knulst, A.C.

AU - van der Ent, C.K.

AU - van Baarle, D.

AU - Wauben, M.H.M.

AU - Rots, N.Y.

AU - Sanders, E.A.M.

AU - Benders, M.J.N.L.

AU - Meulenbroek, L.A.M.P.

AU - Stahl, B.

AU - Kraneveld, A.D.

AU - Buiteman, B.J.M.

AU - Voogt, T.

AU - van der Meij, B.

AU - Lerkvaleekul, B.

AU - Voogd, E.

AU - Lalmahomed, T.A.

AU - Brus, I.M.

AU - van Meerwijk, D.M.M.

AU - Jepma, S.I.E.

AU - PRIMA Initiative Group

PY - 2022/12

Y1 - 2022/12

N2 - Background: Many studies support the protective effect of breastfeeding on respiratory tract infections. Although infant formulas have been developed to provide adequate nutritional solutions, many components in human milk contributing to the protection of newborns and aiding immune development still need to be identified. In this paper we present the methodology of the “Protecting against Respiratory tract lnfections through human Milk Analysis” (PRIMA) cohort, which is an observational, prospective and multi-centre birth cohort aiming to identify novel functions of components in human milk that are protective against respiratory tract infections and allergic diseases early in life. Methods: For the PRIMA human milk cohort we aim to recruit 1000 mother–child pairs in the first month postpartum. At one week, one, three, and six months after birth, fresh human milk samples will be collected and processed. In order to identify protective components, the level of pathogen specific antibodies, T cell composition, Human milk oligosaccharides, as well as extracellular vesicles (EVs) will be analysed, in the milk samples in relation to clinical data which are collected using two-weekly parental questionnaires. The primary outcome of this study is the number of parent-reported medically attended respiratory infections. Secondary outcomes that will be measured are physician diagnosed (respiratory) infections and allergies during the first year of life. Discussion: The PRIMA human milk cohort will be a large prospective healthy birth cohort in which we will use an integrated, multidisciplinary approach to identify the longitudinal effect human milk components that play a role in preventing (respiratory) infections and allergies during the first year of life. Ultimately, we believe that this study will provide novel insights into immunomodulatory components in human milk. This may allow for optimizing formula feeding for all non-breastfed infants.

AB - Background: Many studies support the protective effect of breastfeeding on respiratory tract infections. Although infant formulas have been developed to provide adequate nutritional solutions, many components in human milk contributing to the protection of newborns and aiding immune development still need to be identified. In this paper we present the methodology of the “Protecting against Respiratory tract lnfections through human Milk Analysis” (PRIMA) cohort, which is an observational, prospective and multi-centre birth cohort aiming to identify novel functions of components in human milk that are protective against respiratory tract infections and allergic diseases early in life. Methods: For the PRIMA human milk cohort we aim to recruit 1000 mother–child pairs in the first month postpartum. At one week, one, three, and six months after birth, fresh human milk samples will be collected and processed. In order to identify protective components, the level of pathogen specific antibodies, T cell composition, Human milk oligosaccharides, as well as extracellular vesicles (EVs) will be analysed, in the milk samples in relation to clinical data which are collected using two-weekly parental questionnaires. The primary outcome of this study is the number of parent-reported medically attended respiratory infections. Secondary outcomes that will be measured are physician diagnosed (respiratory) infections and allergies during the first year of life. Discussion: The PRIMA human milk cohort will be a large prospective healthy birth cohort in which we will use an integrated, multidisciplinary approach to identify the longitudinal effect human milk components that play a role in preventing (respiratory) infections and allergies during the first year of life. Ultimately, we believe that this study will provide novel insights into immunomodulatory components in human milk. This may allow for optimizing formula feeding for all non-breastfed infants.

UR - https://www.scopus.com/pages/publications/85124604169

UR - https://www.scopus.com/inward/citedby.url?scp=85124604169&partnerID=8YFLogxK

U2 - 10.1186/s12879-022-07107-w

DO - 10.1186/s12879-022-07107-w

M3 - Article

SN - 1471-2334

VL - 22

SP - 1

EP - 10

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

IS - 1

M1 - 152

ER -

Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this